2021 Best In KLAS Drug Diversion Monitoring

Decision Insights

Drug Diversion Monitoring 2021

04 January 22 | Jackson Tate and Jennifer Hickenlooper

In the last 12 months, KLAS has interviewed 41 healthcare organizations that have recently purchased a drug diversion monitoring solution or are in the process of doing so. This represents a sharp increase in market activity. Several factors are fueling the growth, including greater awareness of the opioid crisis as well as a greater need during the COVID-19 pandemic for visibility and automation when it comes to managing medication inventories. Additionally, organizations are considering several newer technology options purported to offer more intuitive workflows and more complete investigational tools. This report examines recent and upcoming drug diversion monitoring purchase decisions to determine which vendors are generating the highest interest.

Company/solution	Overall performance score (100-point scale)	Total evaluations	Trend (2020-2021)	Culture	Loyalty	Operations	Product	Relationship	Value

Bluesight Kit Check Bluesight for Controlled Substances	90	n=39	0%	B+	A	A-	B+	A-	A

Omnicell Analytics	69.7	n=25	0%	D+	C-	C	C	C	D

Bluesight Medacist RxAuditor	68.9	n=21	0%	B-	F	C	D	C+	C+
	50.0	100.0

Company/solution	Trend (2020-2021)	Culture	Loyalty	Operations	Product	Relationship	Value

Bluesight Kit Check Bluesight for Controlled Substances 90 n=39 COMMENTS	0%	B+	A	A-	B+	A-	A
Omnicell Analytics 69.7 n=25	0%	D+	C-	C	C	C	D
Bluesight Medacist RxAuditor 68.9 n=21	0%	B-	F	C	D	C+	C+

Company/solution	Overall performance score (100-point scale)	Total evaluations	Culture	Loyalty	Operations	Product	Relationship	Value

HelioMetrics Drug Diversion Analytics * L	76.5	n=9	C-	C+	C	C+	B-	B

Imprivata FairWarning Drug Diversion Monitoring * L	93.9	n=13	A+	A+	A-	A-	A	A+

Wolters Kluwer Invistics Flowlytics * L	80.2	n=6	C	B	C+	C+	A-	B+

Company/solution	Overall performance score (100-point scale)	Total evaluations

HelioMetrics Drug Diversion Analytics * L culture C- loyalty C+ operations C product C+ relationship B- value B	76.5	n=9

Imprivata FairWarning Drug Diversion Monitoring * L culture A+ loyalty A+ operations A- product A- relationship A value A+	93.9	n=13

Wolters Kluwer Invistics Flowlytics * L culture C loyalty B operations C+ product C+ relationship A- value B+	80.2	n=6

Drug Diversion Monitoring

Past Drug Diversion Monitoring Awards

Contact KLAS

Tell us about your organization

How can we help you?